商品编号


CHI-MF-11135-C025



品牌


Adipogen



公司


Adipogen



公司分类


Proteins



Size

25 ?g

商品信息


More Information



Product Details



Synonyms

Interleukin-35



Product Type

Protein



Properties



Source/Host

CHO cells



Sequence

A soluble dimeric fusion protein consisting of the extracellular domain of mouse IL12a subunit (aa 23-215) is fused to the Fc region of human IgG1, and the mouse Ebi3 subunit (aa 23-228) linked to IL12a by disulfide bonds.



Crossreactivity

Mouse



BIOLOG
ical Activity

Bioactivity was measured in a cell proliferation assay of Con A activated mouse splenocytes.



Purity

≥98% (SDS-PAGE)



Endotoxin Content

<0.06eu mu;g="" protein="" (lal="" test;="" lonza).="">0.06eu>



Reconstitution

Reconstitute at 100μg/ml in sterile PBS.



Formulation

Lyophilized from 0.2μm-filtered solution in PBS.



Other Product Data

NCBI reference NP_056581.1: Ebi3 subunit (mouse)
NCBI reference NP_032377.1: IL-12a subunit (mouse)



Declaration

Manufactured by Chimerigen.



Shipping and Handling



Shipping

BLUE ICE



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

Avoid freeze/thaw cycles.



Use/St
ABI
lity

Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.



Documents



MSD
S

No



Product Specification Sheet



Datasheet


Download PDF





Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells'
ABI
lity to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy. Recently, insufficient IL-35 levels were shown to play a pivotal role in the development of type 1 diabetes (T1D) and autoimmune diseases.


Product References

Interleukin-35 admi
NIST
ration counteracts established murine type 1 diabetes - poss
IBL
e involvement of regulatory T cells: K. Singh, et al.; Sci. Rep.
5,
ID12633 (2015)

Cytokine modulation by IL-35 in mice with allergic rhinitis: M. Yokota, et al.; Am. J. Rhinol. Allergy
29,
251 (2015)

Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice: Z. Cai, et al.; Clin. Exp. Immunol.
181,
253 (2015)

Intranasal admi
NIST
ration of IL-35 inhibits allergic responses and symptoms in mice with allergic rhinitis: M. Suzuki, et al.; Allergol. Int.
(Epub ahead of print)
(2016)

IL-35 suppresses lipopolysaccharide-induced airway eosinophilia in EBI3-deficient mice: K. Kanai, et al.; J. Immunol.
198,
119 (2017)